The effect of intra-vitreal injection of bevacizumab for vascular endothelial factor-related intraocular diseases.

The effect of intra-vitreal injection of bevacizumab for vascular endothelial factor-related intraocular diseases. - The effcet of intra-vitreal bevacizumab.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013974

Enrollment

100

Registered

2014-05-19

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choroidal neovascularization, retinal vein occlusion, diabetic retinopathy, diabetic maculopathy, neovascular glaucoma

Interventions

Intravitreal injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients at Matsumoto Dental University with choroidal neovasucularization, retinal vein occlusion, diabetic retionopathy, uveitis, and neovascular glaucoma.

Exclusion criteria

Exclusion criteria: Patietns with uncontroled hypertension or with systemic risk factors of cerebral infarction or cardial infarction.

Design outcomes

Primary

Measure	Time frame
Varidation on the visula acuity at 1, 3, 6, 12 months after intravitreal injection	—

Secondary

Measure	Time frame
Examination of macular forrmation and thickness by optical coherence tomography	—

Countries

Japan

Contacts

Public ContactKouichi Ohta

Matsumoto Dental University Ophthalmology

ohta@po.mdu.ac.jp0263-51-2360

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026